Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis

Vaccine

Volumn 30, Issue 34, 2012, Pages 5086-5093

  Agallou, Maria ^a   Smirlis, Despina ^a   Soteriadou, Ketty P ^a   Karagouni, Evdokia ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

CpG ODNs; DCs based vaccine; Histone H1; IFN ; IL 10; IL 12; Murine visceral leishmaniasis

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HISTONE H1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA INFANTUM HISTONE H1; LEISHMANIA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL COUNT; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; LEISHMANIA INFANTUM; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; BONE MARROW CELLS; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; HISTONES; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; SPLEEN;

EID: 84863776517     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.075     Document Type: Article

References (47)

1. World Health Organization [Internet]. Geneva, Switzerland; 2011. Available from: http://www.who.int/leishmaniasis/en/index.html.
2. Goto H., Lindoso J.A. Immunity and immunosuppression in experimental visceral leishmaniasis. Braz J Med Biol Res 2004, 37(4):615-623.
3. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 1991, 146(8):2763-2770.
4. Melby P.C., Ogden G.B., Flores H.A., Zhao W., Geldmacher C., Biediger N.M., et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 2000, 68(10):5595-5602.
5. Probst P., Stromberg E., Ghalib H.W., Mozel M., Badaro R., Reed S.G., et al. Identification and characterization of T cell-stimulating antigens from Leishmania by CD4T cell expression cloning. J Immunol 2001, 166(1):498-505.
6. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004, 116(2):259-272.
7. Papageorgiou F.T., Soteriadou K.P. Expression of a novel Leishmania gene encoding a histone H1-like protein in Leishmania major modulates parasite infectivity in vitro. Infect Immun 2002, 70(12):6976-6986.
8. Fasel N.J., Robyr D.C., Mauel J., Glaser T.A. Identification of a histone H1-like gene expressed in Leishmania major. Mol Biochem Parasitol 1993, 62(2):321-323.
9. Smirlis D., Bisti S.N., Xingi E., Konidou G., Thiakaki M., Soteriadou K.P. Leishmania histone H1 overexpression delays parasite cell-cycle progression, parasite differentiation and reduces Leishmania infectivity in vivo. Mol Microbiol 2006, 60(6):1457-1473.
10. Carmelo E., Martinez E., Gonzalez A.C., Pinero J.E., Patarroyo M.E., Del Castillo A., et al. Antigenicity of Leishmania braziliensis histone H1 during cutaneous leishmaniasis: localization of antigenic determinants. Clin Diagn Lab Immunol 2002, 9(4):808-811.
11. Soto M., Requena J.M., Quijada L., Perez M.J., Nieto C.G., Guzman F., et al. Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Clin Exp Immunol 1999, 115(2):342-349.
12. Soto M., Requena J.M., Quijada L., Gomez L.C., Guzman F., Patarroyo M.E., et al. Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis. Clin Exp Immunol 1996, 106(3):454-461.
13. Soto M., Requena J.M., Quijada L., Garcia M., Guzman F., Patarroyo M.E., et al. Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol Lett 1995, 48(3):209-214.
14. Requena J.M., Alonso C., Soto M. Evolutionarily conserved proteins as prominent immunogens during Leishmania infections. Parasitol Today 2000, 16(6):246-250.
15. Carrion J., Folgueira C., Alonso C. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine 2008, 26(20):2537-2544.
16. Iborra S., Soto M., Carrion J., Alonso C., Requena J.M. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine 2004, 22(29-30):3865-3876.
17. Carrion J., Nieto A., Soto M., Alonso C. Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice. Microbes Infect 2007, 9(6):735-743.
18. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
19. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
20. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61(3):248-255.
21. Berberich C., Ramirez-Pineda J.R., Hambrecht C., Alber G., Skeiky Y.A., Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003, 170(6):3171-3179.
22. Ghosh M., Pal C., Ray M., Maitra S., Mandal L., Bandyopadhyay S. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J Immunol 2003, 170(11):5625-5629.
23. Ahuja S.S., Reddick R.L., Sato N., Montalbo E., Kostecki V., Zhao W., et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 1999, 163(7):3890-3897.
24. Agallou M., Margaroni M., Karagouni E. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine 2011, 29(31):5053-5564.
25. Papadopoulou G., Karagouni E., Dotsika E. ISCOMs vaccine against experimental leishmaniasis. Vaccine 1998, 16(9-10):885-892.
26. Carrion J., Nieto A., Iborra S., Iniesta V., Soto M., Folgueira C., et al. Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol 2006, 28(5):173-183.
27. Stobie L., Gurunathan S., Prussin C., Sacks D.L., Glaichenhaus N., Wu C.Y., et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A 2000, 97(15):8427-8432.
28. Bhaumik S., Basu R., Sen S., Naskar K., Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 2009, 27(9):1306-1316.
29. Gonzalo R.M., Rodriguez J.R., Rodriguez D., Gonzalez-Aseguinolaza G., Larraga V., Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect 2001, 3(9):701-711.
30. Yamakami K., Akao S., Sato M., Nitta Y., Miyazaki J., Tadakuma T. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection. Parasitol Int 2001, 50(2):81-91.
31. Masina S., Gicheru M., Demotz S.O., Fasel N.J. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen. J Infect Dis 2003, 188(8):1250-1257.
32. Engwerda C.R., Murphy M.L., Cotterell S.E., Smelt S.C., Kaye P.M. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 1998, 28(2):669-680.
33. Satoskar A., Bluethmann H., Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 1995, 63(12):4894-4899.
34. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., Th1 Murray H.W. Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 1994, 62(3):1058-1063.
35. Huang L.R., Chen F.L., Chen Y.T., Lin Y.M., Kung J.T. Potent induction of long-term CD8+ T cell memory by short-term IL-4 exposure during T cell receptor stimulation. Proc Natl Acad Sci U S A 2000, 97(7):3406-3411.
36. Stager S., Smith D.F., Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000, 165(12):7064-7071.
37. Mukherjee P., Ghosh A.K., Ghose A.C. Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes. Immunol Lett 2003, 86(2):131-138.
38. Melby P.C., Yang Y.Z., Cheng J., Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 1998, 66(1):18-27.
39. Basu A., Chakrabarti G., Saha A., Bandyopadhyay S. Modulation of CD11C+ splenic dendritic cell functions in murine visceral leishmaniasis: correlation with parasite replication in the spleen. Immunology 2000, 99(2):305-313.
40. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A 1999, 96(12):6970-6975.
41. Moreno J., Nieto J., Masina S., Canavate C., Cruz I., Chicharro C., et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 2007, 25(29):5290-5300.
42. Rhalem A., Sahibi H., Guessous-Idrissi N., Lasri S., Natami A., Riyad M., et al. Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum. Vet Parasitol 1999, 81(3):173-184.
43. Lehmann J., Enssle K.H., Lehmann I., Emmendorfer A., Lohmann-Matthes M.L. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000, 20(1):63-77.
44. Engwerda C.R., Kaye P.M. Organ-specific immune responses associated with infectious disease. Immunol Today 2000, 21(2):73-78.
45. Bodas M., Jain N., Awasthi A., Martin S., Penke Loka R.K., Dandekar D., et al. Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy. J Immunol 2006, 177(7):4636-4643.
46. Babaloo Z., Kaye P.M., Eslami M.B. Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans R Soc Trop Med Hyg 2001, 95(1):85-88.
47. Bacellar O., D'Oliveira A., Jeronimo S., Carvalho E.M. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 2000, 12(8):1228-1231.